Colorectal cancer’s stealthy progression and often late-stage diagnosis have made traditional screening a challenging endeavor, despite the availability of colonoscopy and stool-based testing methods. One of the critical hurdles in combating this disease lies in achieving high individual compliance to screening regimens, which is complicated by various social determinants and structural barriers within communities. To circumvent these challenges, the research team investigated whether molecular markers of colorectal cancer could be detected and quantified in community wastewater, offering a non-invasive, population-wide early warning system.

Wastewater has long been recognized as a valuable reservoir of biological signatures, encompassing a myriad of substances excreted in feces and urine. Prior research has applied wastewater epidemiology to track viral outbreaks and community drug use, but its application to cancer biomarkers in a population surveillance context is pioneering. The study centered on CDH1, a gene associated with cancer progression, particularly colorectal cancer. This gene’s product plays a pivotal role in cell adhesion, and its aberrant expression is a hallmark of several cancers, making it an attractive biomarker candidate for monitoring.

The researchers conducted their study in Jefferson County, Kentucky, analyzing patient records and state cancer registry data over a span of nearly three decades. Geospatial mapping techniques identified clusters with significantly elevated colorectal cancer incidence, demarcated by regions having at least four cases within a half-mile radius. These clusters were then juxtaposed with low-incidence control regions, providing a comparative framework to assess the feasibility of wastewater marker detection correlating with disease prevalence.

Sampling was meticulously designed to capture the diurnal variation in wastewater composition. Researchers collected 175 milliliters of wastewater from four distinct sewersheds representing high and low disease incidence zones, at three time points—7 AM, 10 AM, and 1 PM—on a single day in late July 2023. These samples underwent rigorous molecular analysis targeting human RNA biomarkers. Specifically, CDH1 levels were measured alongside GAPDH, a ubiquitous housekeeping gene involved in glycolytic metabolism, which functioned as an internal control to normalize the cancer marker data, compensating for variability in sample content.

The findings revealed that all sampled sewersheds contained detectable levels of both CDH1 and GAPDH transcripts. Notably, the average ratio of CDH1 to GAPDH was markedly elevated in high-incidence clusters. One cluster exhibited ratios nearly an order of magnitude greater than the comparison group, suggesting that wastewater analysis could indeed reflect underlying cancer prevalence at a community level. Intriguingly, one cluster with the highest known colorectal cancer patient density showed a CDH1/GAPDH ratio nearly eight times that of the control area, mirroring clinical data and lending credence to the method’s sensitivity.

Yet, the study authors exercise caution in interpreting these results, highlighting the exploratory nature of the work as a proof of concept. The precise relationship between the CDH1:GAPDH ratio in wastewater and the incidence or stage distribution of colorectal cancer remains to be delineated. Additionally, the method cannot distinguish between newly diagnosed, ongoing, or undiagnosed cases, representing a limitation for epidemiological interpretation. The study’s relatively small sample size and confinement to a single geographical area further temper the generalizability of the findings and underscore the necessity for larger-scale validation.

Furthermore, there exist technical challenges intrinsic to wastewater-based surveillance of cancer biomarkers. RNA molecules are inherently unstable and susceptible to degradation in the environmental milieu of sewage systems. Effective detection thus requires sensitive extraction and amplification protocols capable of discerning low-abundance transcripts amidst a complex chemical background. Additionally, variations in population size, wastewater flow rates, and contributions from non-residential sources introduce confounding factors that must be rigorously accounted for in analytical modeling.

Despite these challenges, the potential advantages of wastewater surveillance for colorectal cancer are compelling. It offers a scalable and cost-efficient means to monitor disease trends at the population level, potentially identifying emerging hotspots that warrant focused screening efforts. Detecting elevated cancer markers in wastewater before clinical cases are registered in state databases could provide public health officials with lead-time, enabling more proactive and localized interventions. This methodological complement could be especially impactful in reaching underserved communities where access to traditional screening is limited.

The study’s authors emphasize that burgeoning colorectal cancer rates among younger populations necessitate novel public health strategies. While existing modalities like colonoscopies remain gold standards, their reliance on individual participation restricts their reach. Wastewater surveillance circumvents this barrier, offering a community-wide lens that does not depend on self-reporting or healthcare engagement, thus democratizing early detection capabilities. Integrating molecular data from sewage with epidemiological frameworks could herald a new paradigm in cancer surveillance and prevention.

Looking forward, the researchers advocate for comprehensive research agendas that address current knowledge gaps. Key priorities include refining biomarker panels to improve specificity and sensitivity, standardizing sampling protocols to account for temporal and spatial variability, and developing predictive models correlating wastewater signals to population disease metrics. Multisite studies encompassing diverse demographics and environmental contexts will be essential to validate and optimize this promising approach. Interdisciplinary collaboration across molecular epidemiology, environmental sciences, and clinical oncology will be imperative to realize its full potential.

This pioneering investigation inaugurates a horizon where wastewater monitoring transcends infectious disease tracking and enters the realm of chronic disease surveillance, shining light on cancer detection at a community scale. The prospect of harnessing municipal sewage as a mirror reflecting collective health status charts a bold course towards more timely, equitable, and effective cancer control strategies. While nascent, the promise embodied in wastewater-based colorectal cancer surveillance signals a transformative advancement in public health diagnostics.

Subject of Research: People
Article Title: Using wastewater for population-level colorectal cancer surveillance: a future research agenda
News Publication Date: 17-Mar-2026
Web References: http://dx.doi.org/10.1136/jech-2025-224253
Keywords: Colorectal cancer, Wastewater, Biomarkers, CDH1, Epidemiology, Public health surveillance, Early cancer detection, Molecular biology, Environmental health

Breast-conserving surgery (BCS) aims to excise malignant tumours while sparing as much healthy tissue as possible. The success of these procedures hinges on the precise identification of tumour margins. Failure to completely remove cancerous cells often results in re-excision surgeries, which increase patient distress and healthcare costs while potentially impacting survival outcomes. Current intraoperative margin assessment techniques, however, can be costly, time-consuming, or insufficiently accurate.

Enter stereoscopic optical palpation, an approach that leverages the biomechanical attribute of increased stiffness typically exhibited by cancerous breast tissue compared to normal tissue. By capturing pairs of high-resolution images using a specialized camera system, SOP generates three-dimensional stress maps illustrating mechanical pressure distribution on tissue surfaces. This innovative method capitalizes on differential tissue elasticity to pinpoint tumour boundaries rapidly and non-invasively.

The study conducted an extensive evaluation of SOP’s diagnostic capabilities using freshly excised breast tissue samples from 48 patients. These samples underwent immediate imaging within minutes of excision to simulate real-time surgical assistance. For each specimen, the SOP system captured stereoscopic photographs and computed stress maps that highlighted areas subjected to varying mechanical pressure across the tissue’s surface.

To rigorously validate SOP’s accuracy, researchers meticulously co-registered the generated stress maps with histopathological analyses—the gold standard for cancer diagnosis. They focused on regions of interest located within one millimeter of the tissue margins, as cancer presence within this critical boundary significantly influences surgical decision-making. These regions were randomly grouped into ten sets to facilitate robust classifier training and testing via 10-fold cross-validation, strengthening the reliability of findings.

Remarkably, histopathologic evaluation revealed that 11.3% of the analyzed margin regions harbored cancer cells. When applying the SOP technique coupled with automatic classification algorithms, the sensitivity—reflecting the true positive rate of detecting cancerous tissue—reached an impressive 82.1%. Equally notable, the specificity, indicating the accurate identification of benign tissue, stood at 83.6%. These metrics highlight SOP’s potential as a reliable intraoperative tool to distinguish malignant from non-malignant margins effectively.

A critical parameter emerging from the analysis was the mean stress threshold used to identify positive cancer margins, calculated at 10.1 kilopascals. This numerical benchmark provides a practical reference point for future applications of SOP, aiding surgeons and software systems in making definitive margin evaluations during procedures.

Beyond the quantitative results, the study underscores SOP’s inherent advantages: it offers simplicity, rapid processing, and cost-effectiveness. Unlike existing methods requiring extensive equipment or specialist intervention, SOP’s camera-based setup can integrate easily into surgical workflows. Generating detailed stress maps within two minutes post-image capture facilitates immediate feedback, supporting intraoperative decision-making without delays.

The implications of incorporating SOP into breast cancer surgery are profound. By providing accurate, real-time margin assessments, SOP may significantly reduce rates of incomplete tumour excision and the consequent need for additional surgeries. This improvement can diminish patient anxiety, reduce healthcare expenditures, and potentially enhance long-term outcomes by decreasing local recurrence rates post-BCS.

This study’s demonstration of SOP’s diagnostic feasibility represents an important step toward clinical translation. However, further investigations involving larger cohorts and diverse tumour subtypes will be necessary to confirm and refine the technology’s utility. Additionally, integration with surgical instruments or robotic systems could pave the way for fully automated, precision-guided tumour resections.

The research team’s innovative approach reflects a broader trend emphasizing biomechanical properties as valuable diagnostic biomarkers in oncology. By leveraging tumor tissue stiffness differences, researchers are opening new avenues for non-invasive cancer detection that complement traditional histopathology and molecular techniques.

As breast cancer remains one of the most prevalent cancers affecting women globally, innovations like SOP bear immense promise for improving surgical outcomes and patient quality of life. The synthesis of optical elastography with machine learning classifiers exemplifies the power of interdisciplinary collaboration, uniting physics, engineering, pathology, and clinical expertise.

The technical elegance of SOP lies in its stereoscopic imaging capability, which captures depth information unavailable to conventional 2D photography. This volumetric data enriches the mechanical stress mapping process, enhancing spatial resolution and diagnostic precision. Moreover, the rapid computational algorithms translating images into actionable maps represent an advancement in real-time medical imaging.

Looking forward, researchers envision expanding SOP’s applications beyond breast cancer. Tumour margin assessment in other solid tumors such as melanoma, pancreatic, or brain cancers could benefit from similar biomechanical profiling. The generalizability of the technique and adaptability for various surgical environments underscore its broad potential impact.

In conclusion, the diagnostic feasibility study published in BMC Cancer heralds stereoscopic optical palpation as a promising, affordable, and accurate method for intraoperative breast tumour margin assessment. By facilitating immediate, precise differentiation between malignant and benign tissues, SOP has the potential to transform breast-conserving surgeries, reducing re-excision rates and improving patient outcomes worldwide.

Subject of Research: Diagnostic feasibility of stereoscopic optical palpation for breast tumour margin assessment.

Article Title: Diagnostic feasibility study of stereoscopic optical palpation for breast tumour margin assessment.

Article References:
Fang, Q., Sanderson, R.W., Zilkens, R. et al. Diagnostic feasibility study of stereoscopic optical palpation for breast tumour margin assessment.
BMC Cancer 25, 1793 (2025). https://doi.org/10.1186/s12885-025-14871-w

Image Credits: Scienmag.com

DOI: 19 November 2025

The principle behind these 4D-printed microdevices lies in their dynamic response capability, which transcends traditional 3D printing by incorporating time as the fourth dimension. This temporal factor enables the devices to morph in response to specific biochemical cues present in the patient’s bloodstream, thereby allowing real-time, spatially resolved molecular detection. The dynamic nature of the material substrates utilized in the printing process facilitates adaptive interactions with ctDNA and miRNA biomarkers, essential indicators of tumor presence and progression in pancreatic cancer patients.

Pancreatic ductal adenocarcinoma (PDAC), the predominant form of pancreatic cancer, often releases trace amounts of nucleic acids such as ctDNA and miRNAs into circulation. These molecular fragments serve as minimally invasive biomarkers that reflect tumor burden, genetic mutations, and therapeutic response. However, the reliable detection of these biomarkers is hampered by their low abundance and the complexity of bodily fluids. The newly developed microdevices leverage highly sensitive sensing elements integrated within a flexible, programmable matrix, enhancing affinity and specificity toward these nucleic acid targets.

The microdevices employ functionalized nanomaterials embedded within the 4D-printed architecture to facilitate selective binding of ctDNA and miRNA molecules. These nanomaterials, often composed of gold nanoparticles, graphene derivatives, or molecularly imprinted polymers, contribute to the amplification of detection signals and reduce background noise. This integration significantly improves the limit of detection, making it feasible to identify minute concentrations of tumor-derived genetic material at early disease stages.

Spatial resolution is another key advantage delivered by these microdevices. By localizing multiple sensing units within a single platform, it becomes possible to map the heterogeneity of tumor-specific biomarkers within the bloodstream. This spatial mapping uncovers variations in genetic mutations or expression profiles that may correlate with tumor microenvironment changes or metastatic potential. Consequently, clinicians can obtain a multidimensional molecular portrait of the cancer, informing more accurate prognosis and tailored treatment regimens.

A crucial feature facilitating these capabilities is the programming of stimuli-responsive materials within the 4D printing process. These materials react to environmental cues such as pH, temperature, or enzymatic activity, altering their conformation and exposing or concealing sensor sites on demand. Through such fine-tuned control, the devices can cycle between binding and release states, enabling repeated measurements from a single sample and reducing patient discomfort associated with frequent blood draws.

The fabrication process integrates advanced additive manufacturing techniques, including digital light processing (DLP) and two-photon polymerization (TPP), enabling microscale precision. This allows the construction of complex three-dimensional microarchitectures with intricate channels and sensor arrays necessary for fluid handling and molecular recognition. The spatial arrangement ensures optimal exposure of target molecules to sensing surfaces, maximizing interaction efficiency.

Importantly, the deployment of these microdevices aligns with the burgeoning field of liquid biopsy, which aims to revolutionize cancer diagnosis and monitoring by replacing invasive tissue biopsies with simple blood tests. Compared to conventional diagnostic tools, liquid biopsy provides the advantage of continuous, real-time tracking of tumor dynamics, enabling rapid detection of relapse or resistance mutations. The incorporation of 4D-printed devices in this realm enhances sensitivity and adaptability beyond current technologies.

From a clinical perspective, the adoption of such microdevices could markedly improve patient outcomes. Early detection of pancreatic cancer biomarkers through sensitive and spatially resolved platforms allows clinicians to initiate treatment when tumors are at their most manageable stages. Moreover, the ability to monitor treatment efficacy via successive measurements of ctDNA and miRNA facilitates timely therapeutic adjustments, potentially minimizing side effects and enhancing efficacy.

Beyond pancreatic cancer, the technology holds promise for broader oncological applications. The principles of spatiotemporal biomarker detection can be adapted to other malignancies characterized by distinct nucleic acid signatures circulating within bodily fluids. Such versatility underscores the transformative potential of 4D-printed microdevices as a universal diagnostic tool across multiple cancer types and possibly other diseases marked by specific biomolecular markers.

In addition to diagnostic capabilities, these devices may aid in drug development and clinical trials by providing dynamic insights into tumor biology under therapeutic stress. The real-time data on circulating nucleic acids can inform pharmacodynamics and identify patient subsets likely to respond to novel agents, streamlining the path toward personalized oncology therapeutics.

Data handling and integration represent critical components accompanying these advancements. The microdevices can be coupled with artificial intelligence (AI)-driven analytic platforms capable of interpreting vast multiplexed datasets generated during screening. AI algorithms can discern patterns and trends invisible to traditional analysis, further personalizing patient care and enhancing predictive accuracy.

Despite exciting progress, challenges remain before widespread clinical integration. Issues related to manufacturing scalability, biocompatibility, stability in complex biological environments, and regulatory approvals require systematic tackling. Continued interdisciplinary collaboration among engineers, molecular biologists, clinicians, and data scientists is paramount to refining device performance and ensuring safety and efficacy.

Environmental responsiveness embedded in the microdevice design also opens avenues for integration with wearable or implantable platforms, enabling continuous home-based monitoring. Such innovations would drastically reduce healthcare burdens and empower patients with real-time health insights, facilitating proactive disease management.

Ethical considerations arise concerning data privacy, especially given the sensitive genomic information these devices handle. Robust frameworks for patient consent and data protection must accompany technological proliferation to maintain trust and compliance with evolving healthcare regulations.

This pioneering research into 4D-printed microdevices not only shines a light on the potential revolution in pancreatic cancer management but also heralds a new era in the marriage of additive manufacturing with molecular diagnostics. As these technologies mature, they promise to rewrite the paradigms of early cancer detection, treatment monitoring, and personalized medicine, ultimately transforming patient care and clinical outcomes worldwide.

Subject of Research:
4D-printed microdevices for spatiotemporal detection of circulating tumor DNA (ctDNA) and microRNA (miRNA) biomarkers in pancreatic cancer.

Article Title:
4D-printed microdevices for spatiotemporal detection of ctDNA and miRNA in pancreatic cancer: an in-depth review.

Article References:
Ebrahim, N.A.A., Farghaly, T.A. & Soliman, S.M.A. 4D-printed microdevices for spatiotemporal detection of ctDNA and miRNA in pancreatic cancer: an in-depth review. Med Oncol 42, 462 (2025). https://doi.org/10.1007/s12032-025-03021-8

Image Credits:
AI Generated